Multivariate analysis further demonstrated the significant contribution of higher GKN2 expression to better outcomes of the patients (hazard ratio, 0.464; 95% CI, 0.239–0.901; P = 0.023; Table 1) and indicated that GKN2 was an independent and significant prognostic factor for patients with GC treated with oxaliplatin. Here, GKN2 is linked to gastric cancer.